November 13th, 2025
11 a.m. EST

As the cell and gene therapy (CGT) pipeline continues to expand, the industry faces a critical bottleneck: limited, CGT-experienced site capacity. Traditional sites are oversubscribed, while qualified but underutilized or naïve sites remain untapped. Sponsors need more CGT capable centers to support safe, high-quality trials, and bridging this gap is essential to advancing CGT programs efficiently and effectively.

This webinar will bring together perspectives from a sponsor, CRO, clinical site, and institutional biosafety committee (IBC) expert to explore strategies for expanding and optimizing CGT trial sites. Attendees will gain insight into:

Identifying and evaluating emerging sites, including how sponsors can build trust in those that are naïve or underutilized.
CRO strategies to de-risk site selection, accelerate start-up activities, and provide ongoing training and operational support.
Site-level best practices for creating CGT centers of excellence, fostering cross-departmental coordination, and developing sustainable institutional processes.
Regulatory readiness, with practical guidance on IBC definitions, requirements, and pathways to accelerate study start-up through central IBC models and concierge services.

By examining the site capacity issue from multiple perspectives, this session will highlight actionable approaches for sponsors to expand their site networks with confidence. Attendees will leave with a clearer understanding of how to leverage untapped sites, foster collaboration, and streamline study initiation helping ensure their CGT programs have the infrastructure needed to succeed.

Registration Coming Soon